| Q46317390 | A Tumor-Specific Cascade Amplification Drug Release Nanoparticle for Overcoming Multidrug Resistance in Cancers. |
| Q64917268 | A pH/ROS Cascade-Responsive Charge-Reversal Nanosystem with Self-Amplified Drug Release for Synergistic Oxidation-Chemotherapy. |
| Q34104079 | Afatinib and its encapsulated polymeric micelles inhibits HER2-overexpressed colorectal tumor cell growth in vitro and in vivo |
| Q36695591 | An NQO1 substrate with potent antitumor activity that selectively kills by PARP1-induced programmed necrosis |
| Q89834201 | Anticancer Potential of Resveratrol, β-Lapachone and Their Analogues |
| Q28534416 | Characterization of lung cancer by amide proton transfer (APT) imaging: an in-vivo study in an orthotopic mouse model |
| Q30583249 | Colocalized delivery of rapamycin and paclitaxel to tumors enhances synergistic targeting of the PI3K/Akt/mTOR pathway |
| Q36471467 | Depleting Tumor-NQO1 Potentiates Anoikis and Inhibits Growth of NSCLC. |
| Q39617420 | Dimeric naphthoquinones, a novel class of compounds with prostate cancer cytotoxicity |
| Q38267035 | Drug delivery and nanodetection in lung cancer |
| Q57150128 | Encapsulation of nor-β-lapachone into poly(d,l)-lactide--glycolide (PLGA) microcapsules: full characterization, computational details and cytotoxic activity against human cancer cell lines |
| Q49108416 | Enhancing Oral Absorption of β-Lapachone: Progress Till Date. |
| Q36716649 | Esterase-activatable β-lapachone prodrug micelles for NQO1-targeted lung cancer therapy |
| Q38168377 | Exploring polymeric micelles for improved delivery of anticancer agents: recent developments in preclinical studies. |
| Q34995515 | Hydroxycamptothecin-loaded Fe3O4 nanoparticles induce human lung cancer cell apoptosis through caspase-8 pathway activation and disrupt tight junctions |
| Q89484746 | Inhibition of TXNRD or SOD1 overcomes NRF2-mediated resistance to β-lapachone |
| Q38726394 | Leveraging an NQO1 Bioactivatable Drug for Tumor-Selective Use of Poly(ADP-ribose) Polymerase Inhibitors. |
| Q46086889 | Lysosome-oriented, dual-stage pH-responsive polymeric micelles for β-Lapachone delivery |
| Q27346846 | Modulating endogenous NQO1 levels identifies key regulatory mechanisms of action of β-lapachone for pancreatic cancer therapy |
| Q92851091 | Modulation of Nqo1 activity intercepts anoikis resistance and reduces metastatic potential of hepatocellular carcinoma |
| Q37954497 | Molecular-targeted nanotherapies in cancer: enabling treatment specificity |
| Q35856376 | Multifunctional unimolecular micelles for cancer-targeted drug delivery and positron emission tomography imaging |
| Q37440695 | NQO1-Mediated Tumor-Selective Lethality and Radiosensitization for Head and Neck Cancer. |
| Q64388243 | NQO1-dependent, Tumor-selective Radiosensitization of Non-small Cell Lung Cancers |
| Q38247299 | Nanomedicines for cancer therapy: state-of-the-art and limitations to pre-clinical studies that hinder future developments. |
| Q47165034 | Nanoparticle as a novel tool in hyperthermic intraperitoneal and pressurized intraperitoneal aerosol chemotheprapy to treat patients with peritoneal carcinomatosis. |
| Q38603364 | Nanotechnology-enabled delivery of NQO1 bioactivatable drugs |
| Q90649930 | Nanotherapeutics for Treatment of Pulmonary Arterial Hypertension |
| Q93000585 | PET imaging of occult tumours by temporal integration of tumour-acidosis signals from pH-sensitive 64Cu-labelled polymers |
| Q39099843 | Pharmacokinetics and derivation of an anticancer dosing regimen for the novel anti-cancer agent isobutyl-deoxynyboquinone (IB-DNQ), a NQO1 bioactivatable molecule, in the domestic felid species |
| Q57461599 | Phase 1 study of ARQ 761, a β-lapachone analogue that promotes NQO1-mediated programmed cancer cell necrosis |
| Q50233354 | PhytoNanotechnology: Enhancing Delivery of Plant Based Anti-cancer Drugs |
| Q39004214 | Preclinical Pharmacokinetic Evaluation of β-Lapachone: Characteristics of Oral Bioavailability and First-Pass Metabolism in Rats |
| Q34227677 | Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. |
| Q34047248 | Prodrug strategy to achieve lyophilizable, high drug loading micelle formulations through diester derivatives of β-Lapachone. |
| Q42409402 | Prostate Cancer Radiosensitization through Poly(ADP-Ribose) Polymerase-1 Hyperactivation |
| Q35705835 | RETRACTED: NAD(P)H:quinone oxidoreductase 1 protects lungs from oxidant-induced emphysema in mice |
| Q38702949 | Recent updates in utilizing prodrugs in drug delivery (2013-2015). |
| Q38191981 | Review of poly (ADP-ribose) polymerase (PARP) mechanisms of action and rationale for targeting in cancer and other diseases. |
| Q35593948 | SoNar, a Highly Responsive NAD+/NADH Sensor, Allows High-Throughput Metabolic Screening of Anti-tumor Agents |
| Q36619072 | Superparamagnetic iron oxide nanoparticles: amplifying ROS stress to improve anticancer drug efficacy |
| Q38762468 | Synthesis and antitumor activity of selenium-containing quinone-based triazoles possessing two redox centres, and their mechanistic insights. |
| Q28395166 | The pursuit of oncotargets through understanding defective cell regulation |
| Q64239757 | Tumor-Specific Drug Release and Reactive Oxygen Species Generation for Cancer Chemo/Chemodynamic Combination Therapy |
| Q36316513 | Tumor-selective use of DNA base excision repair inhibition in pancreatic cancer using the NQO1 bioactivatable drug, β-lapachone |
| Q33767952 | Tumor-selective, futile redox cycle-induced bystander effects elicited by NQO1 bioactivatable radiosensitizing drugs in triple-negative breast cancers |
| Q28543502 | UDP-glucuronosyltransferase 1A determinates intracellular accumulation and anti-cancer effect of β-lapachone in human colon cancer cells |